Phase 2 Pancreatic Cancer Trial, Recruiting NCT05088798 Sponsor: Washington University School of Medicine Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 2 Pancreatic Cancer Trial, Recruiting

NCT05088798
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a condition called hyperinsulinemic hypoglycemia (where the body produces too much insulin, causing dangerously low blood sugar levels), confirmed through blood tests or specific medical tests.
  • People for whom standard medications used to treat this condition (diazoxide or octreotide) have not worked.
  • People (or their parents or legal guardians, if the person is a child) who have given written agreement to take part in the trial.
  • People whose specialist doctor has decided that standard medical treatment is no longer a safe option and that surgery is needed to prevent serious low blood sugar episodes and protect brain health.

Who may not be able to join:

  • People who have another serious illness or health condition that the trial doctors believe would make participation too risky.
  • People for whom an MRI scan is not safe (though in some of these cases, a different type of scan called a PET/CT scan may be used instead — confirm with trial site).
  • Children or individuals whose parents or guardians are not willing to consider surgery as a treatment option.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Ana Maria Arbelaez, MD, MSCI, Washington University School of Medicine

Phone: 314-747-4659

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
10 September 2020
Est. completion
1 January 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Increase Access to 18F-DOPA PET/MRI (or PET/CT) for patients with HI who failed medical therapy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov